Patent Assignment
Reel/Frame 050727/0652
Change of Address
Recorded: 2019-10-15
Pages: 10
Assignor
ALFASIGMA S.P.A.
Executed: 2018-05-04
Assignee
ALFASIGMA S.P.A.
VIA RAGAZZI DEL '99 N. 5, BOLOGNA, 40133, ITALY
Covered Properties
(86)
Carnitine and Inositol Phosphate-Containing Composition Useful as Dietary Supplement or Drug
Patent:
6,565,876 →
Application:
09/720,099 →
Treating chronic uremic patients undergoing periodical dialysis
Patent:
6,335,369 →
Application:
09/761,639 →
Methods and Compositions Using Sulodexide for the Treatment of Diabetic Nephropathy
Treating Chronic Uremic Patients Undergoing Periodical Dialysis
Salts of L-Carnitine and Lower Alkanoyl L-Carnitine
Patent:
6,703,042 →
Application:
09/979,880 →
Treating Chronic Uremic Patients Undergoing Periodical Dialysis
Composition for Prevention and/or Treatment of Vascular Diseases, Comprising Propionyl L-Carnitine and Coenzyme Q10
Double Salts of Fumaric Acid with a Carnitine and an Amino Acid and Food Supplements, Dietary Supplements and Drugs Containing Same
Solid Compositions Suitable for Oral Administration Containing Non-Hygroscopic Salts of L-Carnitine and the Alkanoyl L-Carnitines with Taurine Chloride and Glycine Chloride
Aminoderivatives of Biotin and Their Conjugates with Macrocyclic Chelating Agents
Container for Vial of Radiopharmaceutical and Set for Its Infusion in a Patient or for Its Transfer Elsewhere
Anti-Human Tenascin Monoclonal Antibody
Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
Medicament for the Two-Step Perioperative Therapy of Solid Tumours
Anti-Human Tenascin Monoclonal Antibody
Bifidobacteria and Preparations Containing Them
Treating Chronic Uremic Patients Undergoing Periodical Dialysis
Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in Medicinal Preparations
Ultrafine-L-Carnitine, Methods of Preparing the Same, Compositions Containing the Same, and Methods of Using the Same
Acetyl L-Carnitine for Prevention of Painful Peripheral Neuropathy in Patients with Type 2 Diabetes
Method for Treating Intermittent Claudication Comprising the Administration of Propionyl L-Carnitine and a Concomitant Physical Training
Dietary Supplement Energy-Providing to Skeletal Muscles
Use of L-Carnitine for the Treatment of Cardiovascular Diseases
Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations
Gastroresistant Pharmaceutical Formulations Containing Rifaximin
Use of Polymorphic Forms of Rifaximin for Medical Preparations
Aminoderivative of Biotin and Their Conjugates with Macrocyclic Chelating Agents
Synthesis of Deoxybiotinyl Hexamethylenediamine-Dota
Biotin Diaminoderivatives and Their Conjugates with Macrocyclic Chelating Agents
Vector for Efficient Selection and/or Maturation of an Antibody and Uses Thereof
Polymorphic Forms Alpha, Beta and Gamma of Rifaximin
Processes for the Production of Polymorphic Forms of Rifaximin
Pharmaceutical Compositions Comprising Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin
Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia
Anti-Human Tenascin Monoclonal Antibody
Use of Polyols to Obtain Stable Polymorphous Forms of Rifaximin
Rifamycin Derivatives
Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin
A Method Useful for the Prevention of Type 2 Diabetes and Its Complications in Pre-Diabetic Patients with Insulin Resistance
Anti-Epcam Antibody and Uses Thereof
Oxidized Avidin with High Residency Time in the Treated Tissues
Container for Vial of Radiopharmaceutical and Set for Its Infusion in a Patient or for Its Transfer Elsewhere
Use of L-Carnitine for the Treatment of Cardiovascular Diesases
Composition Useful for the Prevention or Reduction of the Progression of Prostate Cancer
Polymorphic Forms Alpha, Beta and Gamma of Rifaximin
Processes for the Production of Polymorphic Forms of Rifaximin
Pharmaceutical Compositions Comprising Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin
Use of Polymorphic Forms of Rifaximin for Medical Preparations
Long-Term Treatment of Symptomatic Heart Failure
Agent for Preventing and/or Treating Functional Gastrointestinal Disorder
Oxidated Derivatives of Triazolylpurines Useful as Ligands of the Adenosine A2A Receptor and Their Use as Medicaments
Compositions for Bowel Cleansing and Use Thereof
Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations
Use of Polyols to Obtain Stable Polymorphous Forms of Rifaximin
Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections
Rifaximin Powder, Process for Preparing the Same and Controlled Release Compositions Containing Said Rifaximin Useful for Obtaining a Long-Lasting Effect
Sulodexide for Use in the Treatment of Pathologies Wherein Metalloproteinases Are Involved
Pharmaceutical Compositions Comprising Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin
Polymorphic Forms Alpha, Beta and Gamma of Rifaximin
Rifamycin Derivatives
Assays and Methods for Selecting a Treatment Regimen for a Subject with Depression
Assays and Methods for Selecting a Treatment Regimen for a Subject with Depression
Vector for Efficient Selection and/or Maturation of an Antibody and Uses Thereof
Patent:
45,968 →
Application:
13/831,258 →
Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof
Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations
COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY
Acetyl L-Carnitine for the Preparation of a Medicament for the Prevention of Painful Peripheral Neuropathy in Patients with Type 2 Diabetes
Gastroresistant Pharmaceutical Formulations Containing Rifaximin
Composition Useful for the Treatment of Lipid Metabolism Disorders
New Thio Derivatives Bearing Lactams as Potent Hdac Inhibitors and Their Uses as Medicaments
Pharmaceutical Composition of Oxidised Avidin Suitable for Inhalation
Rifaximin Powder, Process for Preparing the Same and Controlled Release Compositions Containing Said Rifaximin Useful for Obtaining a Long-Lasting Effect
Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations
Composition Useful for the Prevention or Reduction of the Progression of Prostate Cancer
Rifaximin Derivative and Uses Thereof
Method of Treating Gerd with Alpha and Beta Galactosidases
Rifaximin Derivative and Uses Thereof
Composition Useful as a Dietary Supplement
Use of Polyols to Obtain Stable Polymorphous Forms of Rifaximin
Rifaximin Derivative and Uses Thereof
New Solvated Crystal Form of Rifaximin, Production, Compositions and Uses Thereof
Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations
Gastroresistant Pharmaceutical Formulations Containing Rifaximin
Application:
16/379,709 →
Publication:
US 2020/0000726
Polymorphic Forms Alpha, Beta and Gamma of Rifaximin
Application:
16/409,324 →
Publication:
US 2019/0263829
Pharmaceutical Compositions Comprising Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin
Application:
16/409,398 →
Publication:
US 2019/0263830
Nsaid Administration and Related Compositions, Methods and Systems
Application:
16/457,814 →
Publication:
US 2019/0388411
Related Assignments
(5)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 7, 2012
From: TECNOGEN S.P.A.
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE, S.P.A.
Reel/Frame 029258/0849 →
Assignment of Assignor's Interest
Apr 29, 2015
From: ALFA WASSERMANN, INC.
To: ALFA WASSERMANN S.P.A.
Reel/Frame 035532/0728 →
Merger
Nov 14, 2017
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 045061/0567 →
Merger
Nov 14, 2017
From: ALFA WASSERMANN S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 045061/0645 →
Merger
Nov 14, 2017
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 044760/0906 →